Sentinel lymph node (SLN) biopsy has revolutionized breast cancer management and has been generally accepted as a mainstay in lymph node evaluation for breast cancer patients. Still, there are many controversies that surround both the surgical technique involved and how the SLNs should be evaluated intraoperatively. The ramifications of isolated tumor cells and micrometastases and the need for axillary node dissection in all SLN-positive patients remain subjects of debate. This article reviews the literature with regard to these issues and presents the current state of the science of SLN biopsy.
Sentinel Lymph Node Biopsy Technique
Giuliano et al. utilized a peri-areolar blue dye injection to identify the sentinal lymph nodes in the axilla. 1 Generally, the blue dye travels quickly to the first draining lymph nodes in the axilla. Therefore, the dye is injected just after induction of anaesthesia intraoperatively. A small incision is made in the axilla and blue lymphatic channels are traced to blue SLNs, which are then sent for pathologic evaluation. While this technique does not allow for pre-operative identification of the lymph node basin involved, the vast majority of primary breast cancers drain to the ipsilateral axilla and SLNs may be found in this location.
Krag et al. used an alternative technique of injecting a radioactive
tracer into the breast and a hand-held gamma probe intraoperatively to identify the SLNs. 2 The radioactive tracer tends to take longer to reach the axillary SLNs and therefore is generally injected about an hour prior to the biopsy. Some have found, however, that taking into consideration the half-life of the tracer, one may inject the tracer the day prior to surgery with equivalent success. 3 This technique allows for pre-operative imaging with lymphoscintigraphy to map drainage patterns of the breast and identify where the SLNs may be found.
While this technique is useful in melanoma, where the drainage patterns of a tumor may be variable, lymphoscintigraphy has been shown to be of little benefit in breast cancer. 4 One exception to this, however, is for mapping of internal mammary lymph nodes. While some surgeons will use pre-operative imaging to identify patients in whom an internal mammary SLN biopsy may be performed, many will not use this information to change their management. 5 Furthermore, most patients with internal mammary drainage will also have axillary SLNs identified and the rate of finding a positive axillary SLN appears to be the same regardless of drainage pattern. 5 Therefore, unless the finding of positive internal mammary SLNs will change management, the utility of lymphoscintigraphy may be limited.
However, patients who present with recurrent breast cancer who have had previous axillary surgery may have alternate drainage patterns and may benefit from lymphoscintigraphy. 6 While using either blue dye or radioactive tracer allows for successful SLN mapping, using a combination approach with both agents has been
shown to be associated with a higher SLN identification rate. 7 In a metaanalysis, Kim et al. found that the SLN identification rates of studies using blue dye alone (n=18), radiocolloid alone (n=16), or both (n=34) were 83.1, 89.2, and 91.9 %, respectively (p=0.007). 8 Similarly, the falsenegative rates were 10.9, 8.8, and 7.0 % for each of these groups, respectively (p=0.047). 8 Traditionally, a SLN is defined as:
• the hottest node;
• any blue node;
• any node at the end of a blue lymphatic channel;
• any node that has ex vivo counts greater than 10 % of the hottest node; and
• any palpably suspicious node.
Despite removing all of the nodes that meet these criteria, on average only two SLNs are identified. Some have argued that given that the first positive SLN is generally identified within the first three SLNs removed, further SLNs need not be removed. 9 Larger studies, however, found that to abort the SLN biopsy procedure at three nodes when other nodes that met the criteria of being SLNs remained would miss the first positive SLN in a subset of patients.
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Intraoperative Pathologic Evaluation Table 1 ). More recently, intraoperative molecular assays based on polymerase chain reaction (PCR) technology have been evaluated and found to have a fairly high sensitivity (see Table 2 ).
Caution should be exercised, however, in the interpretation of pathology results of SLNs. As SLNs are scrutinized more vigorously than routine axillary lymph nodes, smaller foci of metastases may be identified. Using immunohistochemistry, serial sectioning, and/or molecular techniques, studies have found that metastases will be found in 4-33 % of nodenegative patients (see Table 3 ). The sixth edition of the American Joint Commission on Cancer Staging System has defined metastases measuring less than 0.2 mm as ITCs. 13 While a number of studies have debated the significance of ITCs, these are considered node-negative.
Patients who have metastases measuring 0.2-2.0 mm, however, are classified as having micrometastases and are considered node-positive.
Studies have found non-SLN metastases in 0-9 % of patients with ITCs and in 22-33 % of patients with micrometastases in their SLNs (see Table  4 ). 
Prediction Models
Given that the 25-year follow-up data from the landmark NSABP B-04 trial showed no difference in survival for node-positive patients who received ALND compared with those who did not, 19 the need for completion ALND in SLN-positive patients may be questioned. While ALND certainly may improve staging and local control, a number of studies have found that many patients with SLN metastases will have no further disease in the axilla (see Table 5 ). • pathologic tumor size;
• grade;
• lymphovascular invasion;
• multifocality;
• estrogen receptor status;
• the number of positive and negative SLNs; and
• the method used to identify SLN metastases (immunohistochemistry, routine hematoxylin and eosin staining, serial sectioning with hematoxylin and eosin or frozen section). (73 %) had no further non-SLN metastases. A score was developed using three factors: if the ratio of involved SLN to total number of SLNs removed was 1 or more, 2 points were assigned, a ratio between 0.5 and 1 was given 1 point, and a ratio below 0.5 scored zero points.
Macrometastasis in the SLN was given two points, and its absence was given zero points. Tumor size scored zero points if ≤10mm, 1.5 points for tumors measuring between 11 and 20mm, and 3 points if >20 mm.
Patients with scores of 3.5 or less had a 97.3 % chance of having no further non-SLN metastases. Therefore, regardless of the development of clinical prediction models to predict the absence of non-SLN metastases, most surgeons proceed with ALND based on intraoperative pathologic assessment of SLNs.
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Studies are ongoing to incorporate molecular studies to current clinical prediction models, with the objective to improve the ability to identify patients who will not have any further axillary metastases.
Conclusion
SLN biopsy has become the mainstay of axillary staging of breast cancer patients and involves a multidisciplinary effort between surgeons, pathologists, nuclear medicine physicians and others. As this technique has evolved, however, nuances have emerged in terms of the technique itself and how these nodes should be evaluated pathologically.
The greater scrutiny with which the SLNs are evaluated has led to some patients being upstaged. The implications of ITCs and micrometastases on outcomes remain an area of debate. Nonetheless, patients with tumor deposits less than 0.2mm are considered node-negative and will generally not proceed to completion ALND. Those with larger deposits may proceed to immediate ALND based on intraoperative pathologic evaluation. While a proportion of these patients will have no further axillary disease, prediction models to identify these patients continue to be refined. 
